Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

BACKGROUND AND OBJECTIVE: Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated with chronic kidney disease. This study evaluated the effects of moderate hepatic impairment on roxadustat pharmacokinetics, pharmacodynami...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Drug Investig
Main Authors: Groenendaal-van de Meent, Dorien, Adel, Martin den, Noukens, Jan, Rijnders, Sanne, Krebs-Brown, Axel, Mateva, Lyudmila, Alexiev, Assen, Schaddelee, Marloes
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2016
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4987405/
https://ncbi.nlm.nih.gov/pubmed/27352308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-016-0422-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados